Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks (approximately 9 ...
If you're apprehensive about getting an intravitreal injection for age-related macular degeneration (AMD), you're not alone. Ophthalmologist Monika Fleckenstein, MD, explains the procedure, how it can ...
ANI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN, a fluocinolone acetonide intravitreal implant, allowing it to be used ...
Biogen’s Apellis acquisition consolidates a complement franchise spanning retinal and renal indications, with near-term label ...
September 21, 2012 — The US Food and Drug Administration (FDA) has approved aflibercept injection (Eylea, Regeneron Pharmaceuticals) for treating macular edema following central retinal vein occlusion ...
Please provide your email address to receive an email when new articles are posted on . SAR446597 is designed to inhibit C1s and factor Bb in the complement pathway. Fast track designation expedites ...
LONG BEACH, Calif. -- Methotrexate, during and after surgery for primary retinal detachment, has produced "amazing" early results in preventing proliferative vitreoretinopathy (PVR), according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results